Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fertility Preservation | 8 | 2025 | 61 | 3.660 |
Why?
|
| Semen Preservation | 2 | 2025 | 16 | 1.660 |
Why?
|
| Cryopreservation | 6 | 2025 | 78 | 1.420 |
Why?
|
| Ovarian Reserve | 3 | 2023 | 12 | 1.170 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2026 | 61 | 1.080 |
Why?
|
| Neoplasms | 5 | 2025 | 2985 | 0.960 |
Why?
|
| Infertility, Female | 3 | 2023 | 147 | 0.950 |
Why?
|
| Doxorubicin | 2 | 2023 | 290 | 0.880 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2023 | 40 | 0.880 |
Why?
|
| Spermatozoa | 2 | 2025 | 254 | 0.840 |
Why?
|
| Cancer Survivors | 2 | 2025 | 274 | 0.820 |
Why?
|
| Pregnancy Outcome | 3 | 2026 | 614 | 0.820 |
Why?
|
| Infertility, Male | 2 | 2022 | 296 | 0.750 |
Why?
|
| Directive Counseling | 1 | 2019 | 24 | 0.590 |
Why?
|
| Melanoma | 1 | 2026 | 927 | 0.580 |
Why?
|
| Counseling | 1 | 2020 | 235 | 0.580 |
Why?
|
| Fertilization in Vitro | 5 | 2024 | 151 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1332 | 0.500 |
Why?
|
| Patient Selection | 1 | 2020 | 725 | 0.500 |
Why?
|
| Oocytes | 4 | 2026 | 282 | 0.480 |
Why?
|
| Ovulation Induction | 4 | 2024 | 38 | 0.470 |
Why?
|
| Preimplantation Diagnosis | 3 | 2014 | 28 | 0.430 |
Why?
|
| Pregnancy | 15 | 2026 | 7402 | 0.390 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 2602 | 0.380 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 620 | 0.380 |
Why?
|
| Granulosa Cells | 3 | 2022 | 140 | 0.310 |
Why?
|
| Cyclophosphamide | 2 | 2023 | 427 | 0.310 |
Why?
|
| Female | 26 | 2026 | 70427 | 0.280 |
Why?
|
| Young Adult | 5 | 2026 | 10015 | 0.260 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2020 | 266 | 0.250 |
Why?
|
| Humans | 28 | 2026 | 130556 | 0.240 |
Why?
|
| NEDD8 Protein | 1 | 2026 | 20 | 0.240 |
Why?
|
| Sperm Banks | 1 | 2025 | 8 | 0.240 |
Why?
|
| Blastocyst | 2 | 2013 | 73 | 0.240 |
Why?
|
| Sperm Injections, Intracytoplasmic | 2 | 2013 | 50 | 0.230 |
Why?
|
| Adult | 16 | 2026 | 31157 | 0.230 |
Why?
|
| Pregnancy, Ectopic | 1 | 2005 | 21 | 0.230 |
Why?
|
| Uterine Perforation | 1 | 2004 | 2 | 0.220 |
Why?
|
| Hysterosalpingography | 1 | 2004 | 6 | 0.220 |
Why?
|
| Chromosomes | 1 | 2004 | 120 | 0.210 |
Why?
|
| Aneuploidy | 1 | 2004 | 136 | 0.200 |
Why?
|
| Methotrexate | 1 | 2005 | 339 | 0.200 |
Why?
|
| Paclitaxel | 1 | 2023 | 131 | 0.200 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 404 | 0.190 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 108 | 0.190 |
Why?
|
| Retrospective Studies | 7 | 2026 | 17558 | 0.180 |
Why?
|
| Cell Nucleus | 1 | 2004 | 565 | 0.180 |
Why?
|
| Ovarian Diseases | 1 | 2021 | 23 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2003 | 344 | 0.170 |
Why?
|
| Transcription, Genetic | 1 | 2026 | 1367 | 0.170 |
Why?
|
| Fertility | 1 | 2023 | 261 | 0.160 |
Why?
|
| Premenopause | 1 | 2020 | 33 | 0.160 |
Why?
|
| Mitochondria | 1 | 2026 | 776 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2020 | 46 | 0.160 |
Why?
|
| Gene Expression | 1 | 2004 | 1485 | 0.160 |
Why?
|
| Uterus | 1 | 2024 | 545 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2024 | 946 | 0.150 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2020 | 50 | 0.150 |
Why?
|
| Vincristine | 1 | 2020 | 188 | 0.150 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2019 | 50 | 0.150 |
Why?
|
| Estrogens | 1 | 2020 | 429 | 0.130 |
Why?
|
| Vaccination | 1 | 2023 | 1050 | 0.130 |
Why?
|
| Embryo Transfer | 3 | 2024 | 48 | 0.130 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 231 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 221 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 422 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 462 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2014 | 56 | 0.100 |
Why?
|
| BRCA1 Protein | 1 | 2014 | 79 | 0.100 |
Why?
|
| Male | 5 | 2025 | 64536 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2004 | 742 | 0.090 |
Why?
|
| Parents | 1 | 2019 | 1118 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 3797 | 0.090 |
Why?
|
| Obesity | 1 | 2020 | 2384 | 0.070 |
Why?
|
| Oogenesis | 1 | 2008 | 50 | 0.070 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2008 | 81 | 0.070 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2026 | 85 | 0.060 |
Why?
|
| Middle Aged | 3 | 2023 | 28416 | 0.060 |
Why?
|
| Ubiquitination | 1 | 2026 | 174 | 0.060 |
Why?
|
| Oxidative Phosphorylation | 1 | 2026 | 142 | 0.060 |
Why?
|
| Menstrual Cycle | 1 | 2005 | 32 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 296 | 0.060 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 119 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2024 | 5048 | 0.060 |
Why?
|
| Hyaluronan Synthases | 1 | 2004 | 13 | 0.050 |
Why?
|
| Serum Amyloid P-Component | 1 | 2004 | 14 | 0.050 |
Why?
|
| Blastomeres | 1 | 2004 | 6 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 64 | 0.050 |
Why?
|
| Pregnancy Rate | 1 | 2004 | 39 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2005 | 347 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2026 | 285 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2004 | 63 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 122 | 0.050 |
Why?
|
| Sperm Motility | 1 | 2004 | 113 | 0.050 |
Why?
|
| Embryo Implantation | 1 | 2005 | 219 | 0.050 |
Why?
|
| Live Birth | 1 | 2023 | 70 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2026 | 526 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 288 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2003 | 121 | 0.050 |
Why?
|
| ROC Curve | 1 | 2004 | 611 | 0.050 |
Why?
|
| Acceleration | 1 | 2022 | 26 | 0.050 |
Why?
|
| Follicular Fluid | 1 | 2021 | 6 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 448 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2003 | 363 | 0.040 |
Why?
|
| Wound Healing | 1 | 2004 | 486 | 0.040 |
Why?
|
| Georgia | 1 | 2019 | 46 | 0.040 |
Why?
|
| Proxy | 1 | 2019 | 21 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2004 | 535 | 0.040 |
Why?
|
| Reproductive Health | 1 | 2019 | 48 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 2294 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2026 | 3824 | 0.030 |
Why?
|
| Age Distribution | 1 | 2019 | 423 | 0.030 |
Why?
|
| Endometrium | 1 | 2020 | 292 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 4034 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1590 | 0.030 |
Why?
|
| Adolescent | 3 | 2020 | 20774 | 0.030 |
Why?
|
| Biomarkers | 2 | 2020 | 3386 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1216 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 1343 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3355 | 0.030 |
Why?
|
| Reproductive Behavior | 1 | 2013 | 7 | 0.030 |
Why?
|
| United States | 2 | 2020 | 11882 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2013 | 141 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3320 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2004 | 8545 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5164 | 0.020 |
Why?
|
| Prognosis | 1 | 2019 | 4867 | 0.020 |
Why?
|
| Mice | 1 | 2026 | 18222 | 0.020 |
Why?
|
| Animals | 2 | 2026 | 33866 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2014 | 1106 | 0.020 |
Why?
|
| Cell Survival | 1 | 2008 | 834 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 10967 | 0.010 |
Why?
|
| Texas | 1 | 2013 | 3648 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 424 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 564 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3407 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 20900 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 6093 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 2688 | 0.010 |
Why?
|